260 selected records with a cited source date in 2018, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained PubMed bibliographic metadata for PMID 28370978 at 2026-07-30T21:12:28.721Z. PubMed recorded a metadata revision date of 2018-06-25 and an Entrez history date of 2017-04-04. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.
The official Drugs@FDA dataset lists original submission 1 for NDA 022517 with status AP dated 2018-06-21, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02064348 at 2026-07-30T21:11:31.040Z. Its registry update date was 2018-06-13, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01012089 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-06-06, and PeptideScanner's reviewed identity mapping was daptomycin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 205037 with status AP dated 2018-06-05, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 202471 with status AP dated 2018-06-01, and names bivalirudin among the application record's active ingredients.
PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01718613 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-05-18, and PeptideScanner's reviewed identity mapping was vasopressin.
PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00845507 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-04-20, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206077 with status AP dated 2018-04-11, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2018-07256, attributed to FDA and its parent HHS department, on 2018-04-10. Its official title is “Notice of Approval of Products Under Voucher: Rare Pediatric Disease Priority Review Vouchers,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01137682 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-04-05, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained PubMed bibliographic metadata for PMID 28343991 at 2026-07-30T21:12:28.720Z. PubMed recorded a metadata revision date of 2018-04-05 and an Entrez history date of 2017-03-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.
The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT01777542 at 2026-11-16T17:35:13.282Z. Its registry update date was 2018-03-26, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT01544998 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-03-22, and PeptideScanner's reviewed identity mapping was nesiritide.
PubMed lists PMID 28577097 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2017-06-03 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00966355 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-03-19, and PeptideScanner's reviewed identity mapping was octreotide.
PubMed lists PMID 28672144 in Journal of inorganic biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2017-06-23 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 27586814 in Journal of inorganic biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-08-27 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01496131 at 2026-11-15T21:50:32.222Z. Its registry update date was 2018-03-09, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT02527993 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-03-07, and PeptideScanner's reviewed identity mapping was pasireotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 204693 with status AP dated 2018-03-07, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 6 for the reviewed Lixisenatide label family with a published date of 2018-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01046721 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-03-06, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01680653 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-03-05, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00730171 at 2026-07-30T21:12:47.419Z. Its registry update date was 2018-02-19, and PeptideScanner's reviewed identity mapping was linaclotide.
PubMed lists PMID 8813476 in Digestion as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 1996 (year precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01393704 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02217800 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01103440 at 2026-11-15T21:59:29.646Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 3758119 at 2026-07-30T21:13:34.042Z. PubMed recorded a metadata revision date of 2018-02-14 and an Entrez history date of 1986-01-01. PeptideScanner associated this retained record with the identity slug emideltide. These dates describe PubMed metadata history, not the article's original publication date.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.
The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
PeptideScanner retained PubMed bibliographic metadata for PMID 28887173 at 2026-07-30T21:13:36.164Z. PubMed recorded a metadata revision date of 2018-02-08 and an Entrez history date of 2017-09-10. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT02092597 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-02-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00882557 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02021942 at 2026-11-15T22:05:38.400Z. Its registry update date was 2018-02-05, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT02660346 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-02-01, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00428844 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-31, and PeptideScanner's reviewed identity mapping was daptomycin.
The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00845182 at 2026-07-30T21:12:47.410Z. Its registry update date was 2018-01-18, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01191840 at 2026-11-15T22:01:45.056Z. Its registry update date was 2018-01-05, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02608996 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-01-03, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01134562 at 2026-11-15T22:07:29.454Z. Its registry update date was 2018-01-02, and PeptideScanner's reviewed identity mapping was etelcalcetide.